Patient-reported outcomes after curative treatment for prostate cancer with prostatectomy, primary radiotherapy or salvage radiotherapy

References

• Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352(19):1977–1984. doi: 10.1056/NEJMoa043739.
   PubMed Web of Science ®Google Scholar
• Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373(9660):301–308. doi: 10.1016/S0140-6736(08)61815-2.
   PubMed Web of Science ®Google Scholar
• Hamdy FC, Donovan JL, Lane JA, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415–1424. doi: 10.1056/NEJMoa1606220.
   PubMed Web of Science ®Google Scholar
• Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer (SPCG-15). ClinicalTrials.gov Identifier: NCT02102477. 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT02102477.
   Google Scholar
• Yaxley JW, Coughlin GD, Chambers SK, et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet. 2016;388(10049):1057–1066. doi: 10.1016/S0140-6736(16)30592-X.
   PubMed Web of Science ®Google Scholar
• Coughlin GD, Yaxley JW, Chambers SK, et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study. Lancet Oncol. 2018;19(8):1051–1060. doi: 10.1016/S1470-2045(18)30357-7.
   PubMed Web of Science ®Google Scholar
• Connolly SS, Cathcart PJ, Gilmore P, et al. Robotic radical prostatectomy as the initial step in multimodal therapy for men with high-risk localised prostate cancer: initial experience of 160 men. BJU Int. 2012;109(5):752–759. doi: 10.1111/j.1464-410X.2011.10548.x.
   PubMed Web of Science ®Google Scholar
• Vatne K, Stensvold A, Myklebust T, et al. Pre- and post-prostatectomy variables associated with pelvic post-operative radiotherapy in prostate cancer patients: a national registry-based study. Acta Oncol. 2017;56(10):1295–1301. doi: 10.1080/0284186X.2017.1314006.
   PubMed Web of Science ®Google Scholar
• Teoh M, Clark CH, Wood K, et al. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol. 2011;84(1007):967–996. doi: 10.1259/bjr/22373346.
   PubMed Web of Science ®Google Scholar
• Smit SG, Heyns CF. Management of radiation cystitis. Nat Rev Urol. 2010; 7(4):206–214. doi: 10.1038/nrurol.2010.23.
   PubMed Web of Science ®Google Scholar
• Szymanski KM, Wei JT, Dunn RL, et al. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010;76(5):1245–1250. doi: 10.1016/j.urology.2010.01.027.
   PubMed Web of Science ®Google Scholar
• Ávila M, Patel L, López S, et al. Patient-reported outcomes after treatment for clinically localized prostate cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2018;66:23–44. doi: 10.1016/j.ctrv.2018.03.005.
   PubMed Web of Science ®Google Scholar
• Chien GW, Slezak JM, Harrison TN, et al. Health-related quality of life outcomes from a contemporary prostate cancer registry in a large diverse population. BJU Int. 2017;120(4):520–529. doi: 10.1111/bju.13843.
   PubMed Web of Science ®Google Scholar
• Barocas DA, Alvarez J, Resnick MJ, et al. Association Between radiation therapy, surgery, or observation for localized prostate cancer and Patient-Reported outcomes After 3 years. Jama. 2017;317(11):1126–1140. doi: 10.1001/jama.2017.1704.
   PubMed Web of Science ®Google Scholar
• Hoffman KE, Penson DF, Zhao Z, et al. Patient-Reported outcomes Through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation With or Without androgen deprivation therapy for localized prostate cancer. Jama. 2020;323(2):149–163. doi: 10.1001/jama.2019.20675.
   PubMed Web of Science ®Google Scholar
• Donovan JL, Hamdy FC, Lane JA, et al. Patient-Reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425–1437. doi: 10.1056/NEJMoa1606221.
   PubMed Web of Science ®Google Scholar
• Lawrie TA, Green JT, Beresford M, et al. Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers. Cochrane Database Syst Rev. 2018;1(1):Cd012529.
   PubMedGoogle Scholar
• Epstein JI, Egevad L, Amin MB, et al. The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–252. doi: 10.1097/PAS.0000000000000530.
   PubMed Web of Science ®Google Scholar
• European Association of Urology Guidelines Staging. Available from: https://uroweb.org/guideline/prostate-cancer/chapter/classification-and-staging-systems.
   Google Scholar
• De Carlo F, Celestino F, Verri C, et al. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: surgical, oncological, and functional outcomes: a systematic review. Urol Int. 2014;93(4):373–383. doi: 10.1159/000366008.
   PubMed Web of Science ®Google Scholar
• Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–1060. doi: 10.1016/S1470-2045(16)30102-4.
   PubMed Web of Science ®Google Scholar
• Siegmann A, Bottke D, Faehndrich J, et al. Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective study. Strahlenther Onkol. 2011;187(8):467–472. doi: 10.1007/s00066-011-2229-3.
   PubMed Web of Science ®Google Scholar
• Briganti nomogram 2018. https://www.evidencio.com/models/show/1555.
   Google Scholar
• European Association of Urology Guidelines Treatment. https://uroweb.org/guidelines/prostate-cancer/chapter/treatment.
   Google Scholar
• Fosså SD, Storås AH, Steinsvik EA, et al. Psychometric testing of the norwegian version of the expanded prostate cancer index composite 26-item version (EPIC-26). Scand J Urol. 2016;50(4):280–285. doi: 10.3109/21681805.2016.1163617.
   PubMed Web of Science ®Google Scholar
• The Expanded Prostate Cancer Index Composite - Short Form. https://medicine.umich.edu/dept/urology/research/epic.
   Google Scholar
• Scoring Instructions for the Expanded Prostate cancer Index Composite Shurt Form (EPIC-26). https://medicine.umich.edu/sites/default/files/content/downloads/Scoring%20Instructions%20for%20the%20EPIC%2026.pdf.
   Google Scholar
• Skolarus TA, Dunn RL, Sanda MG, et al. Minimally important difference for the expanded prostate cancer index composite short form. Urology. 2015;85(1):101–105. doi: 10.1016/j.urology.2014.08.044.
   PubMed Web of Science ®Google Scholar
• Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250–1261. doi: 10.1056/NEJMoa074311.
   PubMed Web of Science ®Google Scholar
• Ishii K, Yamanaga T, Ogino R, et al. Bowel and urinary quality of life after whole-pelvic versus prostate-only volumetric-modulated arc therapy for localized prostate cancer. Pract Radiat Oncol. 2018;8(2):e49–e55. doi: 10.1016/j.prro.2017.10.005.
   PubMed Web of Science ®Google Scholar
• Caumont F, Conti G, Hurwitz LM, et al. A prospective analysis of health-related quality of life in intermediate and high-risk prostate cancer patients managed with intensity modulated radiation therapy, with vs. without hormonal therapy. Urol Oncol. 2020;38(10):794.e1-794–e9. doi: 10.1016/j.urolonc.2020.02.007.
   Web of Science ®Google Scholar
• Bai M, Gergelis KR, Sir M, et al. Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer. Cancer Med. 2020;9(21):7925–7934. doi: 10.1002/cam4.3414.
   PubMed Web of Science ®Google Scholar
• Akthar AS, Liao C, Eggener SE, et al. Patient-reported outcomes and late toxicity After postprostatectomy intensity-modulated radiation therapy. Eur Urol. 2019;76(5):686–692. doi: 10.1016/j.eururo.2019.05.011.
   PubMed Web of Science ®Google Scholar
• Berlin A, Cho E, Kong V, et al. Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: toxicity, biochemical, and patient-reported health-related quality-of-life outcomes. Pract Radiat Oncol. 2015;5(5):e473–e482. doi: 10.1016/j.prro.2015.02.015.
   PubMedGoogle Scholar
• Corbin KS, Kunnavakkam R, Eggener SE, et al. Intensity modulated radiation therapy after radical prostatectomy: early results show no decline in urinary continence, gastrointestinal, or sexual quality of life. Pract Radiat Oncol. 2013;3(2):138–144. doi: 10.1016/j.prro.2012.05.005.
   PubMedGoogle Scholar
• van Gysen KL, Kneebone AB, Guo L, et al. Health-related quality of life using intensity-modulated radiation therapy for post-prostatectomy radiotherapy. J Med Imaging Radiat Oncol. 2013;57(1):89–96. doi: 10.1111/j.1754-9485.2012.02464.x.
   PubMed Web of Science ®Google Scholar
• Stensvold A, Dahl AA, Brennhovd B, et al. Bother problems in prostate cancer patients after curative treatment. Urol Oncol. 2013;31(7):1067–1078. doi: 10.1016/j.urolonc.2011.12.020.
   PubMed Web of Science ®Google Scholar
• Nezolosky MD, Dinh KT, Muralidhar V, et al. Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urol Oncol. 2016;34(2):57.e15-22–57.e22. doi: 10.1016/j.urolonc.2015.09.002.
   PubMed Web of Science ®Google Scholar
• Van den Broeck T, van den Bergh RCN, Arfi N, et al. Prognostic value of biochemical recurrence Following treatment with curative intent for prostate cancer: a systematic review. Eur Urol. 2019;75(6):967–987. doi: 10.1016/j.eururo.2018.10.011.
   PubMed Web of Science ®Google Scholar
• Tilki D, Preisser F, Graefen M, et al. External validation of the european association of urology biochemical recurrence risk groups to predict metastasis and mortality After radical prostatectomy in a european cohort. Eur Urol. 2019;75(6):896–900. doi: 10.1016/j.eururo.2019.03.016.
   PubMed Web of Science ®Google Scholar